Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/27403
Title: Importance of combined-modality therapy for primary bone lymphoma
Authors: Baiocchi, Otavio Carvalho Guimarães [UNIFESP]
Colleoni, Gisele Wally Braga [UNIFESP]
Rodrigues, Celso Arrais [UNIFESP]
Barton, D. [UNIFESP]
Kerbauy, Fábio Rodrigues [UNIFESP]
Garcia, R. J. [UNIFESP]
Segreto, Roberto Araujo [UNIFESP]
Alves, Antonio Correa [UNIFESP]
Bordin, Jose Orlando [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Keywords: non-Hodgkin's lymphoma
bone lymphoma
treatment
prognosis
Issue Date: 1-Sep-2003
Publisher: Taylor & Francis Ltd
Citation: Leukemia & Lymphoma. Abingdon: Taylor & Francis Ltd, v. 44, n. 10, p. 1837-1839, 2003.
Abstract: Primary bone lymphoma (PBL) is a rare entity and comprises about 5% of all extranodal non-Hodgkin's lymphomas (NHL) and 7% of all primary bone tumors. To date there is no consensus about the optimal treatment for PBL. We retrospectively reviewed all cases of PBL treated at Hospital São Paulo, Brazil, over a 10-year-period (January 1992-January 2002). Medical records of 7 patients with PBL were reviewed and information on age at diagnosis, sex, NHL clinical staging (CS), treatment and response to treatment were retrieved. Five patients (72%) received combined-modality therapy (CMT) and all of them are in complete remission (CR) with a median follow up of 19 months (ranging from 12 to 144 months). We conclude that PBL is a potentially curable malignancy and treatment should be undertaken in a multiprofessional approach, in order to provide the best support which probably has to include chemotherapy, radiotherapy and, for patients with IPI higher than 2, consolidation with stem-cell transplantation.
URI: http://repositorio.unifesp.br/handle/11600/27403
ISSN: 1042-8194
Other Identifiers: http://dx.doi.org/10.1080/1042819031000110937
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.